Abstract
The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
Keywords:
COVID-19 therapy; IL6; SARS-CoV-2; bazedoxifene; cytokine storm; lung failure; raloxifene.
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
MeSH terms
-
Betacoronavirus / drug effects
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / genetics
-
Coronavirus Infections / mortality
-
Coronavirus Infections / virology
-
Cytokines / antagonists & inhibitors
-
Cytokines / genetics
-
Humans
-
Indoles / pharmacology*
-
Interleukin-6 / antagonists & inhibitors
-
Interleukin-6 / genetics
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / genetics
-
Pneumonia, Viral / mortality
-
Pneumonia, Viral / virology
-
Raloxifene Hydrochloride / pharmacology*
-
Receptors, Estrogen / antagonists & inhibitors
-
Respiratory Distress Syndrome / drug therapy*
-
Respiratory Distress Syndrome / prevention & control
-
Respiratory Distress Syndrome / virology
-
SARS-CoV-2
-
Selective Estrogen Receptor Modulators / pharmacology
-
Signal Transduction / drug effects
Substances
-
Cytokines
-
Indoles
-
Interleukin-6
-
Receptors, Estrogen
-
Selective Estrogen Receptor Modulators
-
Raloxifene Hydrochloride
-
bazedoxifene